Literature DB >> 16707275

Progress towards the development of malaria vaccines.

Elissa Malkin1, Filip Dubovsky, Melinda Moree.   

Abstract

The misery and suffering caused worldwide by infection with the malaria parasite, especially Plasmodium falciparum, has been well documented. Although no licensed vaccine against malaria currently exists, progress has accelerated in recent years towards the goal of developing one. Although the complexity of the malaria parasite has made the malaria vaccine development process tenuous, advances in science and in the vaccine development process as well as increases in funding are encouraging. These advances, coupled with the results of the recent clinical trial of the vaccine candidate RTS,S, have added new vigor to the idea that a malaria vaccine is not only possible but probable.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707275     DOI: 10.1016/j.pt.2006.05.002

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  14 in total

1.  Limited polymorphism of the Plasmodium vivax merozoite surface protein 1 gene in isolates from Turkey.

Authors:  Fadile Yildiz Zeyrek; Shin-Ichiro Tachibana; Fehmi Yuksel; Nebiye Doni; Nirianne Palacpac; Nobuko Arisue; Toshihiro Horii; Cevayir Coban; Kazuyuki Tanabe
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

2.  Selective killing of the human malaria parasite Plasmodium falciparum by a benzylthiazolium dye.

Authors:  Jane X Kelly; Rolf W Winter; Theodore P Braun; Myralyn Osei-Agyemang; David J Hinrichs; Michael K Riscoe
Journal:  Exp Parasitol       Date:  2006-12-21       Impact factor: 2.011

3.  Characterisation of PfRON6, a Plasmodium falciparum rhoptry neck protein with a novel cysteine-rich domain.

Authors:  Nicholas I Proellocks; Lev M Kats; David A Sheffield; Eric Hanssen; Casilda G Black; Karena L Waller; Ross L Coppel
Journal:  Int J Parasitol       Date:  2008-11-27       Impact factor: 3.981

Review 4.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

5.  Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.

Authors:  S Olugbile; C Kulangara; G Bang; S Bertholet; E Suzarte; V Villard; G Frank; R Audran; A Razaname; I Nebie; O Awobusuyi; F Spertini; A V Kajava; I Felger; P Druilhe; G Corradin
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

6.  Lineage-specific positive selection at the merozoite surface protein 1 (msp1) locus of Plasmodium vivax and related simian malaria parasites.

Authors:  Hiromi Sawai; Hiroto Otani; Nobuko Arisue; Nirianne Palacpac; Leonardo de Oliveira Martins; Sisira Pathirana; Shiroma Handunnetti; Satoru Kawai; Hirohisa Kishino; Toshihiro Horii; Kazuyuki Tanabe
Journal:  BMC Evol Biol       Date:  2010-02-19       Impact factor: 3.260

Review 7.  Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection.

Authors:  Ivo Mueller; Vasee S Moorthy; Graham V Brown; Peter G Smith; Pedro Alonso; Blaise Genton
Journal:  Vaccine       Date:  2009-07-26       Impact factor: 3.641

8.  Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.

Authors:  Arnoldo Barbosa; Denise Naniche; John J Aponte; M Nelia Manaca; Inacio Mandomando; Pedro Aide; Jahit Sacarlal; Montse Renom; Sarah Lafuente; W Ripley Ballou; Pedro L Alonso
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

9.  A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.

Authors:  Bertrand Lell; Selidji Agnandji; Isabelle von Glasenapp; Sonja Haertle; Sunny Oyakhiromen; Saadou Issifou; Johan Vekemans; Amanda Leach; Marc Lievens; Marie-Claude Dubois; Marie-Ange Demoitie; Terrell Carter; Tonya Villafana; W Ripley Ballou; Joe Cohen; Peter G Kremsner
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

10.  Quantitative PCR evaluation of cellular immune responses in Kenyan children vaccinated with a candidate malaria vaccine.

Authors:  Jedidah Mwacharo; Susanna J Dunachie; Oscar Kai; Adrian V S Hill; Philip Bejon; Helen A Fletcher
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.